Poised to Lead K-Beauty and Pharmaceutical Non-Clinical Market with 'EpiTem-2' Launch

ROKIT Healthcare an AI-driven personalized organ regeneration platform specialist, has announced the full-scale commercialization of 'EpiTem-2,' its 3D bioprinting-based artificial skin organoid. Beginning with sales and research agreements signed with major Korean skin research institutions on October 5th, the company is in ongoing large-scale partnership negotiations with cosmetic ODM and pharmaceutical companies, signaling its accelerated entry into the artificial skin organoid market.

EpiTem-2 is a product that ensures high completeness and reproducibility by precisely fabricating epidermal and full-thickness artificial skin using 3D bioprinting. Notably, it is a solution that precisely aligns with the U.S. FDA's regulatory changes regarding Non-Animal Methods (NAMs). It is immediately applicable for various non-clinical tests, including toxicity assessments, sensitization tests, and whitening efficacy evaluations.

Based on these strengths, EpiTem-2 is positioned to meet the urgent market needs of global cosmetic and pharmaceutical companies that must rapidly transition their testing methods. It is evaluated as a key product that will strengthen ROKIT Healthcare's leading position in the market.

The development of new cosmetics and drugs is increasingly segmented by criteria such as ethnicity and skin type. EpiTem-2 addresses this trend with its 3D printing-based capability to produce customized organoids tailored to specific types. This provides a differentiated competitiveness, making it an attractive next-generation safety and efficacy verification platform for K-beauty and other global cosmetic corporations.

According to the 2025 Regenerative Artificial Skin Market Report, the global artificial skin organoid market is projected to grow from USD 1.69 billion in 2024 to USD 4.92 billion by 2031, reflecting a compound annual growth rate (CAGR) of 16.5%.

Building on its commercial market entry through these initial contracts, ROKIT Healthcare plans to expand collaborations with ODM and pharmaceutical companies, further accelerating its expansion into the artificial skin organoid market.

A ROKIT Healthcare spokesperson commented, “EpiTem-2 demonstrates the expansion of our AI-based personalized organ regeneration technology into the artificial skin sector. We aim to lead the technology standardization of the NAMs market through collaboration with global regulatory bodies.” The spokesperson emphasized, “By securing overseas certifications and expanding our client network, we will establish a global commercialization model capable of generating sustainable revenue.”